| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
ková
ich Kope
ekDepartment of Pharmaceutics and Pharmaceutical Chemistry/Center for Controlled Chemical Delivery (CCCD), University of Utah, Salt Lake City, Utah
The effects of geldanamycin (GA), 17-(3-aminopropylamino)-17-demethoxygeldanamycin (AP-GA), and N-(2-hydroxypropyl)methacrylamide copolymer-AP-GA conjugate [P(AP-GA)] on A2780 human ovarian carcinoma cells at an equitoxic dose (2x IC50) were compared by the gene expression array analysis. All treatments resulted in similar gene expression profiles up to 12 h (e.g., down-regulation of CDK4 and up-regulation of APAF-1), although P(AP-GA)-treated cells showed delayed gene expression because of time-dependent internalization of the conjugate and intracellular drug release from P(AP-GA). However, AP-GA-treated cells showed elevated expression of HSP70 and HSP27 after 6 h compared with that observed by GA and P(AP-GA) treatments. Depletion of C-Raf, an HSP90 client protein, was observed in all treatments up to 12 h. Confocal microscopy using mesochlorin e6 as a model drug revealed that drug release caused by the lysosomal cleavage of glycylphenylalanylleucylglycine oligopeptide spacer, used as GA derivative copolymer attachment/release point, was moderately fast. These results suggested that AP-GA treatment may activate stress-response pathways, whereas P(AP-GA) treatment may suppress them and trigger signaling pathways essential to cell growth arrest and death by inducing an HSP90-active factor. Although GA and P(AP-GA) treatments induced a time-dependent increase in HSP70 and HSP27 protein expression (detected by Western blotting analysis), AP-GA treatment resulted in more rapid and more intense expression of both proteins. Our results suggest that conjugation of AP-GA to N-(2-hydroxypropyl)methacrylamide copolymer may be able to modulate the cell stress responses induced by AP-GA because of differences in its internalization mechanism, subcellular localization, and intracellular concentration gradients.
This article has been cited by other articles:
![]() |
M. R. Dreher and A. Chilkoti Toward a Systems Engineering Approach to Cancer Drug Delivery J Natl Cancer Inst, July 4, 2007; 99(13): 983 - 985. [Full Text] [PDF] |
||||
![]() |
T. Schluep, J. Hwang, J. Cheng, J. D. Heidel, D. W. Bartlett, B. Hollister, and M. E. Davis Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models Clin. Cancer Res., March 1, 2006; 12(5): 1606 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Duncan, M J Vicent, F Greco, and R I Nicholson Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S189 - S199. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schulz, E. Anter, M.-H. Zou, and J. F. Keaney Jr Estradiol-Mediated Endothelial Nitric Oxide Synthase Association With Heat Shock Protein 90 Requires Adenosine Monophosphate-Dependent Protein Kinase Circulation, June 28, 2005; 111(25): 3473 - 3480. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Peng, X. Guo, S. C. Borkan, A. Bharti, Y. Kuramochi, S. Calderwood, and D. B. Sawyer Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes J. Biol. Chem., April 1, 2005; 280(13): 13148 - 13152. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |